title: Beneficial effects of prostacyclin treatment on reperfusion of the myocardium.
abstract: A total of 20 patients with coronary artery disease were studied in order to assess the benefits of prostacyclin administration on reperfusion of the ischaemic myocardium after cardiopulmonary bypass. Ten received prostacyclin (25 ng/kg per min) while ten were untreated controls. There was no difference between groups with regard to age, preoperative ejection fraction and aortic cross-clamping times. There were no in-hospital deaths in either group. The administration of prostacyclin significantly altered the metabolic side effects of reperfusion followed by hypothermic cardioplegic arrest. Myocardial oxygen consumption after cardiopulmonary bypass was significantly higher in the prostacyclin-treated group than in controls (18.5 ml versus 13 ml; P < 0.01). Prostacyclin treatment significantly reduced the leucocyte activity: leukotriene B4 concentrations were 58 pmol/l in prostacyclin-treated patients compared with 93 pmol/l in controls (P < 0.01). Such recovery of metabolic status during reperfusion resulted in better haemodynamic function in patients receiving prostacyclin.
authors.affiliation: Cardiovascular Surgery Clinic, Türkiye Yüksek Ihtisas Hospital, Sihhiye, Ankara.
authors.forename: S F
authors.initials: SF
authors.lastname: Katircioğlu
authors.forename: D S
authors.initials: DS
authors.lastname: Küçükaksu
authors.forename: M
authors.initials: M
authors.lastname: Bozdayi
authors.forename: O
authors.initials: O
authors.lastname: Taşdemir
authors.forename: K
authors.initials: K
authors.lastname: Bayazit
mesh_terms: D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000601:surgery*; D004734:Energy Metabolism / Q000187:drug effects*; D011464:Epoprostenol / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006324:Heart Arrest, Induced; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D007975:Leukotriene B4 / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D009206:Myocardium / Q000378:metabolism*; D010101:Oxygen Consumption / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016277:Ventricular Function, Left / Q000187:drug effects; D016278:Ventricular Function, Right / Q000187:drug effects
chemical_list: D010975:Platelet Aggregation Inhibitors; D007975:Leukotriene B4; D011464:Epoprostenol